Blue California’s Clinical Trial on Cognitive Function and Health Outcomes
Findings from a 16-week study on ErgoActive® Ergothioneine supplementation show promising cognitive, sleep, and liver health benefits.
Rancho Santa Margarita, Calif. (Aug. 7, 2024) – Blue California is excited to announce the publication of the abstract from a recent clinical trial titled, "The Effect of Ergothioneine Supplementation on Cognitive Function and Other Health-Related Outcomes in Older Adults With Subjective Memory Complaints", in Current Developments in Nutrition. The study investigates the effects of ErgoActive® Ergothioneine on cognitive function and health outcomes in older adults.
This randomized, double-blind, placebo-controlled clinical trial involved 147 participants over a 16-week period. Participants were assigned to receive daily doses of 10 mg or 25 mg of ErgoActive® Ergothioneine or a placebo. The primary focus of the study was to assess cognitive function, while secondary outcomes included sleep quality, subjective memory performance, and blood-based markers of health.
The initial results were presented by Dr. May-Zhang at the American Society of Nutrition NUTRITION2024 conference in Chicago, IL.
This study provides new insights into the potential benefits of short-term ErgoActive® ergothioneine supplementation on key health outcomes, including cognitive function, sleep, and liver health," said Dr. Linda May-Zhang, co-author and VP of Innovation at Blue California. "We’re excited to see how these findings contribute to the growing body of evidence supporting ergothioneine’s role in healthy aging.
Key results from the study include:
- Cognitive Improvements: Significant improvements were observed in cognitive domains such as executive function, complex attention, cognitive flexibility, verbal memory, and reaction time in the groups supplemented with ErgoActive®.
- Sleep Quality: ErgoActive® supplemented groups reported significant improvements in sleep onset, indicating a potential benefit of ergothioneine in promoting restful sleep.
- Healthy Ergothioneine Levels & Liver Health: ErgoActive® supplementation led to a dose-dependent increase in blood-plasma ergothioneine levels and reductions in liver enzyme markers (AST and ALT), supporting its role in liver health.
- Prospective Memory: ErgoActive® supplementation improved scores in prospective memory, a critical cognitive function for everyday tasks.
The initial results were presented by Dr. May-Zhang at the American Society of Nutrition NUTRITION2024 conference in Chicago, IL.
As an antioxidant found naturally in certain foods, including mushrooms, ergothioneine is emerging as a key compound in the promotion of overall health and well-being. Blue California’s ErgoActive® L-ergothioneine is produced through a sustainable, bio-based fermentation process, ensuring high purity and batch-to-batch consistency.
Next Steps: The full manuscript is currently being prepared for peer-reviewed publication. With these promising results, future studies are planned to explore long-term benefits in broader populations. Additionally, Blue California is collaborating with other institutions to explore new applications of ergothioneine for human health.
Blue California is a leading developer and manufacturer of nature-based ingredients for dietary supplements, functional foods, and beverages that promote human health. Through innovative science and sustainable production processes, Blue California delivers high-quality ingredients like ErgoActive® Ergothioneine to support a healthier future.
With a commitment to rigorous scientific research, the company aims to address pressing concerns related to aging and healthspan. For more information, visit https://bluecal-ingredients.com/ergothioneine.
ErgoActive® is a registered trademark of Blue California, Inc.
Ergothioneine is also referred to as L-Ergothioneine, (ET) and (ERG).
Media Contact
|
BlueCal PR Blue California 30111 Tomas |